RP902 for cognitive dysfunction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 May 2026: Trial registered, NCT07579884
  2. 14 Jul 2026: Trial started, NCT07579884

The trials

NCT07579884: To Evaluate the Safety and Efficacy of RP902 Tablets

State
Under way
Phase
Phase 2
People
360 planned
Started
14 Jul 2026
Primary completion
May 2029
Arms
RP902 low dose group, RP902 high dose group
Results
None posted
  1. 12 May 2026: Trial registered
  2. 14 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.